Thank you, Jason. After that, we'll provide updates on the significant progress we've made with lonvo-z, which is being developed as a potential one-time treatment for patients with hereditary ...
Primo Brands Corporation (NYSE: PRMB) ("Primo Brands" or the "Company") today announced its results for the fourth quarter and full year ended December 31, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results